gsk peptide has been researched along with nsc 83265 in 1 studies
| Studies (gsk peptide) | Trials (gsk peptide) | Recent Studies (post-2010) (gsk peptide) | Studies (nsc 83265) | Trials (nsc 83265) | Recent Studies (post-2010) (nsc 83265) |
|---|---|---|---|---|---|
| 7 | 1 | 1 | 51 | 0 | 24 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chinen, T; Hayashi, T; Hirota, H; Ishii, Y; Kondo, H; Motoyama, T; Muroi, M; Nagumo, Y; Osada, H; Tarui, Y; Usui, T | 1 |
1 other study(ies) available for gsk peptide and nsc 83265
| Article | Year |
|---|---|
Terpendole E and its derivative inhibit STLC- and GSK-1-resistant Eg5.
Topics: Cell Survival; Cysteine; Diterpenes; Electrophoresis, Gel, Two-Dimensional; HeLa Cells; Humans; Indoles; Kinesins; Kinetics; Magnetic Resonance Spectroscopy; Microtubules; Mutagenesis; Oligopeptides; Proteome | 2014 |